血清晚期糖基化终末产物与心血管-肾脏-代谢（CKM）综合征之间的关联：一项为期3年的纵向队列研究（2019 - 2022年）

Association Between Serum Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A 3-Year Longitudinal Cohort Study (2019-2022).

作者信息

Zhao Hui, Zhang Ze-Wen, Luo Tao, Aili Dilihumaer, Ding Wen-Huan, Li Yuan-Yuan, Gu Yuan-Sheng, Aslibek Shulipan, He Jing-Jing, Yu Wen-Hui, Ma Run-Ze, Gaoshao Anaer, Qiao Ting-Ting, Zhang Guo-Zhen, Lynn Henry S, Du Mu-Long, Dai Jiang-Hong

机构信息

Department of Epidemiology and Health Statistics, School of Public Health, Xinjiang Medical University, Urumqi, China.

Key Laboratory of Special Environment and Health Research in Xinjiang, Urumqi, China.

出版信息

J Diabetes. 2025 Aug;17(8):e70137. doi: 10.1111/1753-0407.70137.

DOI:10.1111/1753-0407.70137

PMID:40841337

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12370401/

Abstract

BACKGROUND

Cardiovascular-kidney-metabolic (CKM) syndrome begins with obesity and glucose abnormalities, advancing to cardiovascular and kidney complications. This study investigates the relationship of advanced glycation end products (AGEs) with CKM syndrome staging and transition patterns.

METHODS

This 3-year longitudinal study (2019-2022) of 1264 adults identified five CKM trajectory groups: Group 1 (stable low-risk, 6.7%, stage 0/1), Group 2 (fluctuating, 15.8%, stages 0/1-2), Group 3 (stable intermediate, 52.8%, stage 2), Group 4 (progressors, 8.9%, to stage 3/4), and Group 5 (stable high-risk, 15.8%, stage 3/4), from baseline distributions of stage 0 (1.6%), 1 (12.3%), 2 (71.0%), 3 (5.8%), and 4 (9.2%). Serum AGEs were quantified by UPLC-MS/MS.

RESULTS

Higher AGEs levels showed significant associations with CKM severity, with each 1-SD increase corresponding to a 30% greater likelihood of advanced staging (95% CI:10%-54%). Quartile analysis revealed a dose-response relationship (Q2:1.66[1.15-2.41]; Q3:1.67[1.12-2.48]; Q4:1.92[1.31-2.81]). Longitudinally, the total AGEs score was significantly associated with CKM transition patterns from 2019 to 2022. The odds ratios (ORs) for Group 2, Group 3, Group 4, and Group 5 compared to Group 1 were 1.61 (1.06-2.45), 1.64 (1.11-2.41), 1.71 (1.07-2.73), and 2.03 (1.32-3.13), respectively.

CONCLUSIONS

These findings suggest that serum AGEs are linked to CKM severity and progression, potentially serving as biomarkers for CKM staging and targets for intervention.

摘要

背景

心血管-肾脏-代谢（CKM）综合征始于肥胖和血糖异常，进而发展为心血管和肾脏并发症。本研究调查了晚期糖基化终产物（AGEs）与CKM综合征分期及转变模式之间的关系。

方法

这项针对1264名成年人的为期3年的纵向研究（2019年至2022年）确定了五个CKM轨迹组：第1组（稳定低风险，6.7%，0/1期），第2组（波动型，15.8%，0/1 - 2期），第3组（稳定中等风险，52.8%，2期），第4组（进展型，8.9%，进展至3/4期），以及第5组（稳定高风险，15.8%，3/4期），基于0期（1.6%）、1期（12.3%）、2期（71.0%）、3期（5.8%）和4期（9.2%）的基线分布。血清AGEs通过超高效液相色谱-串联质谱法（UPLC-MS/MS）进行定量。

结果

较高的AGEs水平与CKM严重程度显著相关，每增加1个标准差，进展至晚期分期的可能性就增加30%（95%置信区间：10% - 54%）。四分位数分析显示存在剂量反应关系（Q2：1.66[1.15 - 2.41]；Q3：1.67[1.12 - 2.48]；Q4：1.92[1.31 - 2.81]）。纵向来看，2019年至2022年期间，AGEs总分与CKM转变模式显著相关。与第1组相比，第2组、第3组、第4组和第5组的比值比（OR）分别为1.61（1.06 - 2.45）、1.64（1.11 - 2.41）、1.71（1.07 - 2.73）和2.03（1.32 - 3.13）。